HOME >> BIOLOGY >> NEWS
The biggest isn't always best when it comes to treating cancer

Developing immunotherapeutic approaches to treat individuals with cancer is an area of intensive investigation. One such approach being developed is the generation of cancer vaccines containing peptides that mimic tumor antigens (known as mimotopes) to induce potent tumor-specific T cell responses. However, previous studies have indicated that the magnitude of a tumor antigenspecific T cell response in vitro does not always correlate with tumor regression in vivo.

Now, in a study appearing online on August 24 in advance of publication in the September print issue of the Journal of Clinical Investigation, Jill Slansky and colleagues from the University of Colorado have shown that mice vaccinated with mimotopes that induce in vitro T cell responses of intermediate magnitude are protected against tumor growth. By contrast, mimotopes that induce in vitro T cell responses of high magnitude do not protect mice from tumor growth. Both types of mimotope caused T cells to infiltrate the tumors, but only the T cells activated by mimotopes inducing in vitro T cell responses of intermediate magnitude produced the soluble factor interferon-gamma, which is important for effective tumor-specific T cell responses. This study has important implications for the further development of cancer vaccines containing mimotopes, as many current studies have used the magnitude of a tumor-specific T cell response to identify the best mimotope for the vaccine.


'"/>

Contact: Karen Honey
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
24-Aug-2006


Page: 1

Related biology news :

1. What we can learn from the biggest extinction in the history of Earth
2. Leanest teens are biggest energy users and consumers
3. Polarsterns biggest fish catch in 24 years of research in Antarctic waters
4. The biggest bug in gut discomfort
5. Yale dean addresses biggest environmental threats in new book
6. Greenhouse theory smashed by biggest stone
7. The biggest family tree ever
8. New evidence indicates biggest extinction wasnt caused by asteroid or comet
9. One Wwox isnt enough (to protect against cancer)
10. In stretching, pain doesnt equal gain; but if NO isnt producing, stretching wont help
11. How sweet it isnt -- preference for alternatives to sugar based on sour, bitter tastes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The biggest isn always best when comes treating cancer

(Date:2/5/2015)... 28, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... Global Online CEO Conference on January 29 th ... Pereira , CEO of NXT-ID will present and host ... Wocket smart wallet and its full suite of biometric ...
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying ... power and potential for genomic science as a means ... disease prevention and treatment.  I was honored to participate ... government-funded precision medicine program. Since the ... science of genomics—from the first sequenced genome of a ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the ... report to their offering. , The ... individual is who she/he is claiming to be, and for ... unique physical characteristics, such as fingerprint, hand or palm print, ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
(Date:3/3/2015)... Experts and industry insiders from around the ... Alltech REBELation exploring innovation, inspiration and world-changing ideas in ... 31st year, Alltech’s annual international conference traditionally draws more ... to join the REBELation at an extra discount registration ... at which point the standard early registration rate will ...
(Date:3/3/2015)... 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), a life sciences ... products for advanced microarray diagnostics, today announced it ... its Management team. In his capacity as CFO ... from a development stage to a commercially successful ... Company,s capital market strategy and to secure funding ...
(Date:3/3/2015)... 3, 2015  Regenicin, Inc. (OTC Bulletin Board: ... development of and commercialization of regenerative cell therapies to ... today that it has received the final payment to ... Inc. (OTC Bulletin Board: AMBS ). ... the final payments due to Regenicin in the amount ...
(Date:3/3/2015)... ROCKVILLE, Md. , March 3, 2015  RegeneRx ... an editorial in the scientific journal, Expert Opinion ... and his colleague, Dr. Zhenggang Zhang , at ... reported that Thymosin beta 4 (TB4) has ... (PNS) remodeling 24 hours or more post-injury, leading to ...
Breaking Biology Technology:World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
Cached News: